Chemo4METPANC - A Phase 2 study with combination Chemotherapy (Gemcitabine andNab-Paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (BL-8040), and immune checkpointblockade (Cemiplimab) in METastatic treatment naïve PANCreas adenocarcinoma.

Contact:

NCT Number:

Protocol:

AAAS9513

Study Status:

Active/Enrolling

Population:

Adult

Phase:

II

You are being invited to take part in this research study because you have been diagnosed with pancreas cancer that has spread to other parts of the body. The purpose of this study is to determine if combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing tumor size and prolonging life in patients with advanced pancreas cancer. The treatment consists of both immunotherapy (cemiplimab and motixafortide) and chemotherapy (gemcitabine and nab-paclitaxel). Gemcitabine and nab-paclitaxel are approved by the Food and Drug Administration (FDA) for treatment of your type of cancer. Cemiplimab is FDA approved for treatment of skin cancer but not for pancreas cancer. Motixafortide has not been tested with the specific immunotherapy (Cemiplimab) and chemotherapy (gemcitabine and nab-paclitaxel) which you will receive and is being tested in this clinical trial.

Are you Eligible? (Inclusion Criteria)

  • you are 18 years of age or older
  • you have confirmed pancreatic cancer that has spread to other parts of your body (is metastatic)
  • you are willing to use birth control while on this study

Specialty Area(s)

Pancreatic Cancer, Immunotherapy

Principal Investigator

Profile Headshot
  • Director of Medical Oncology and Translational Research for The Pancreas Center

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032